Drug intelligence / Profile preview

TLB002

Development stage: Preclinical
Lead developer: TianLi Biotech
Modality: Small Molecules
Administration: Oral

Overview

TLB002 is an oral small molecule drug candidate developed by TianLi Biotech for the treatment of systemic fibrosis and various inflammatory diseases. It functions by modulating Casein kinase 1 delta (CK1δ) and Casein kinase 1 epsilon (CK1ε), which are key regulators in the TGF-β signaling pathway. By inhibiting these kinases, TLB002 aims to suppress the fibrotic and inflammatory processes driven by TGF-β. The drug is currently in the preclinical stage of development.

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)CSNK1D (Casein kinase I delta)CSNK1E (Casein kinase I isoform epsilon)

Beyond the preview

Go deeper on TLB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLB002.

Explore the full profile